Technical Analysis for ELYM - Eliem Therapeutics, Inc

Grade Last Price % Change Price Change
C 3.32 -5.14% -0.18
ELYM closed down 5.14 percent on Wednesday, March 22, 2023, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish -5.14%
Crossed Above 200 DMA Bullish -5.14%
Crossed Above 50 DMA Bullish -5.14%
MACD Bullish Signal Line Cross Bullish -5.14%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 50 DMA about 16 hours ago
Down 1% about 16 hours ago
Rose Above Previous Day's High 5 days ago
200 DMA Resistance 5 days ago
20 DMA Resistance 5 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Eliem Therapeutics, Inc Description

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pain Neuroscience Disorders Chronic Pain Epilepsy Major Depressive Disorder Neurophysiology Neuropathic Pain Treatment Of Major Depressive Disorder Gabaa Receptor Positive Allosteric Modulators Peripheral Neuropathy Perimenopausal Depression

Is ELYM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.51
52 Week Low 2.21
Average Volume 19,026
200-Day Moving Average 3.27
50-Day Moving Average 3.43
20-Day Moving Average 3.37
10-Day Moving Average 3.17
Average True Range 0.35
RSI 50.74
ADX 15.67
+DI 26.43
-DI 19.92
Chandelier Exit (Long, 3 ATRs) 3.18
Chandelier Exit (Short, 3 ATRs) 3.64
Upper Bollinger Bands 3.92
Lower Bollinger Band 2.83
Percent B (%b) 0.45
BandWidth 32.48
MACD Line -0.02
MACD Signal Line -0.03
MACD Histogram 0.013
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.49
Resistance 3 (R3) 3.50 3.47 3.46
Resistance 2 (R2) 3.47 3.42 3.46 3.45
Resistance 1 (R1) 3.39 3.40 3.38 3.38 3.44
Pivot Point 3.36 3.36 3.35 3.35 3.36
Support 1 (S1) 3.28 3.31 3.27 3.27 3.20
Support 2 (S2) 3.25 3.29 3.24 3.19
Support 3 (S3) 3.17 3.25 3.18
Support 4 (S4) 3.16